Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Affimed reports Q1 loss, positive clinical data in cancer treatments

Affimed's Q1 2024 performance showed a net loss but highlighted positive clinical data and progress in cancer treatments.
Despite enrollment delays in the LuminICE trial, Affimed's programs leveraging the innate immune system demonstrate consistency and success.
Addressing financial challenges, patient enrollment issues, and leveraging opportunities in future study phases and partnerships are key for Affimed's growth.

Affimed reports Q3 performance, highlights clinical milestones, and eyes partnerships

Affimed's Q3 2024 performance reflects a net loss of EUR 15.1 million but maintains a solid cash position of EUR 24.1 million.
Management's focus on clinical milestones, safety profiles, and upcoming updates at ASH 2024 demonstrates a commitment to innovation.
Challenges lie in meeting data expectations, navigating partnerships, and balancing financial stability with growth aspirations.
Opportunities abound in showcasing progress at ASH 2024, exploring partnerships, and advancing clinical programs for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.

Affimed reported mixed Q2 earnings that revealed more milestone payments from their partnerships. In addition, Affimed reported a healthy cash position that is expected to last into 2H of 2022.

Affimed: Preparing For A Bullish 2022

HEIDELBERG, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three abstracts with preclinical data of its innate cell engagers have been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 10-14, 2021.

Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2021 Results - Earnings Call Transcript

HEIDELBERG, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the quarter ended June 30, 2021, and provided an update on clinical and corporate progress.

Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

HEIDELBERG, Germany, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release second quarter 2021 results on Wednesday, September 8, 2021, and host a conference call at 8:30 a.m. EDT to discuss financial results and recent corporate developments.

Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021

Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will Affimed N.V. (AFMD) Report Negative Q2 Earnings?

HEIDELBERG, Germany, July 30, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the publication of a comprehensive preclinical in vitro and in vivo data package of its innate cell engager (ICE®) AFM24 (CD16A/EGFR) in mAbs. The published data were the basis for the Investigational New Drug (IND) clearance for Affimed's ongoing Phase 1/2a study with AFM24 monotherapy in patients with EGFR expressing solid tumors. The preclinical data demonstrates AFM24's unique mechanism of action that harnesses the innate immune system to induce tumor cell killing via antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell phagocytosis (ADCP).

Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors

GT Biopharma Inc

Ocugen, Inc.

Former penny stocks biotech analysts are bullish on right now. The post 3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120%

Allakos Inc

Deciphera Pharmaceuticals

Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.

3 Biotech Stocks That Could Double Soon

Affimed recently reported their Q1 earnings that revealed a solid beat on EPS and revenue. However, the company also announced that Genentech has stopped one of their partnered programs. Following the Genentech announcement, the share price has been under pressure. I believe the market is overreacting, which could provide an opportunity to buy.

Affimed: Remaining Bullish Despite Study Discontinuation

Affimed did well in the last 12 months, but has been seeing a correction lately. Given a "data rich" 2021, the correction is not correct.

Affimed: Current Fall And Future Prospects

Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2021 Results - Earnings Call Transcript

HEIDELBERG, Germany, July 01, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the quarter ended March 31, 2021, and provided an update on clinical and corporate progress.

Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress

Affimed (NASDAQ:AFMD) announces its next round of earnings this Thursday, July 01. Here is Benzinga's look at Affimed's Q1 earnings report.

Affimed Earnings Preview

HEIDELBERG, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release first quarter 2021 results on Thursday, July 1, 2021, and host a conference call at 8:30 a.m. EDT to discuss financial results and recent corporate developments.

Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021

HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Ms. Uta Kemmerich-Keil as director on its Supervisory Board effective immediately. The appointment was approved during the Annual General Meeting of Shareholders on June 15, 2021.

Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board

Heidelberg, Germany, May 26, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 8:30 a.m. Eastern Time.

Affimed to Present at the Jefferies Virtual Healthcare Conference 2021

Heidelberg, Germany, May 20, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2021 Annual General Meeting of Shareholders (the “Annual Meeting”) will be held on June 15, 2021 at 17:30 PM CET (11:30 AM EDT). Due to the continuing COVID-19 pandemic and out of concern for the health and safety of shareholders and other attendees, the Annual Meeting will be held virtually and can be followed by visiting www.virtualshareholdermeeting.com/AFMD2021 , in accordance with the instructions provided in the notice of the meeting.  Shareholders will not be able to attend the Annual Meeting in person.

Affimed Announces Virtual Annual General Meeting of Shareholders

Affimed NV (NASDAQ: AFMD) has announced the publication of in vitro and in vivo research of its lead innate cell engager (ICE), AFM13 (CD16A/CD30), combined with healthy donor-derived Natural killer (NK) cells, in Clinical Cancer Research. The preclinical data demonstrated that AFM13 strongly binds to NK cells, including cytokine-activated or cord blood-derived NK (cbNK) cells, resulting in enhanced tumor recognition and antibody-dependent cellular cytotoxicity.

Affimed's AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical Studies

This biotech stock has already produced some big returns this year.

Could Affimed Be a Millionaire-Maker Stock?

AFM13 in combination with natural killer (NK) cells demonstrated improved tumor recognition and enhanced tumor cell killing in vitro and in vivo.

Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer Cells

Affimed (AFMD) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Affimed (AFMD) Enters Overbought Territory

Affimed's wholly-owned pipeline programs continue to report impressive clinical data that supports a long-term investment. I believe is Affimed is trailblazing on a new approach in oncology. The company's three-pronged approach of testing their products as a monotherapy, NK combo, and I-O combo, has revealed impressive results.

Affimed: Wholly-Owned Pipeline Programs Support A Long-Term Investment

The company's latest quarterly update was less than impressive.

Why Affimed N.V. Stock Dropped Today

Affimed N.V. (AFMD) CEO Adi Hoess on Q4 2020 Results - Earnings Call Transcript

News for Affimed Stock (AFMD)